Discovery and in vitro and in vivo activity evaluation of novel baicalein phosphonium salt derivatives targeting mitochondrial MTHFD2 as anti-colon cancer agents
- 3 April 2026
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 175, 109822
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jilin Province (20260102117JC)
This publication has 32 references indexed in Scilit:
- Hit to lead optimization of isopentenyl chalcones as novel MTHFD2 inhibitors for cancer treatment: design, synthesis, in-vitro, in-vivo and in-silico studiesEuropean Journal of Medicinal Chemistry, 2025
- Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological CharacterizationJournal of Medicinal Chemistry, 2024
- TPP-based conjugates: potential targeting ligandsDrug Discovery Today, 2024
- Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platformiMeta, 2022
- A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancerBiochemical and Biophysical Research Communications, 2021
- MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and functionImmunity, 2021
- The Warburg Effect: How Does it Benefit Cancer Cells?Trends in Biochemical Sciences, 2016
- Metabolic Regulation of Apoptosis in Cancer2016
- Mitochondrial membrane potential and reactive oxygen species in cancer stem cellsFamilial Cancer, 2014
- NAD-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase in transformed cells is a mitochondrial enzymeBiochemical and Biophysical Research Communications, 1988